Product Description
SeaGen is developing SGN-30, an intravenously administered recombinant anti-CD30 monoclonal antibody for the potential treatment of Hodgkin's disease, certain non-Hodgkin's lymphomas, specific leukemia, and immunological diseases such as multiple sclerosis and systemic lupus erythematosus. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/16610770/)
Mechanisms of Action: CD30 Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Large-Cell Anaplastic Lymphoma|T-Cell Cutaneous Lymphoma|Hodgkin Lymphoma|Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Sarcoma, Kaposi|Lymphomatoid Papulosis|Primary Cutaneous Anaplastic Large Cell Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2009-00162 | P2 |
Terminated |
Large-Cell Anaplastic Lymphoma|Lymphoma, Non-Hodgkin |
2010-05-01 |
|
| NCI-2009-00407 | P2 |
Terminated |
Lymphoma, Non-Hodgkin|Large-Cell Anaplastic Lymphoma |
2010-01-01 |
|
| NCI-2012-02822 | P2 |
Completed |
Hodgkin Lymphoma |
2008-09-01 |
|
| SG030-0004 | P2 |
Completed |
Primary Cutaneous Anaplastic Large Cell Lymphoma|Lymphoma, Non-Hodgkin|Lymphomatoid Papulosis|Large-Cell Anaplastic Lymphoma |
2007-02-01 |